Jump to content

Tetrahydrocannabinol

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by 68.108.210.247 (talk) at 18:45, 17 July 2007 (→Research: More precise wording to accurately reflect the source given: "temporary psychotic episodes", "cancellation of subsequent groups in the study"). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

"THC" redirects here. For other uses, see THC (disambiguation).
Tetrahydrocannabinol (THC)
Chemical structure of tetrahydrocannabinol

3D structure of tetrahydrocannabinol
Chemical name (−)-(6aR,10aR)-6,6,9-trimethyl-
3-pentyl-6a,7,8,10a-tetrahydro-
6H-benzo[c]chromen-1-ol
Chemical formula C21H30O2
Molecular mass 314.46 g/mol
Glass transition 9.3 °C
Boiling point 155-157 °C (vacuum, 0.07 mbar)
Solubility (water) 2.8 mg/L (23 °C)
Solubility (saline) 0.77 mg/L (NaCl, 0.15 M)
pKa 10.6
log P 3.78 (water @ pH 7 / octanol)
CAS number 1972-08-3

Tetrahydrocannabinol, also known as THC, Δ9-THC, Δ9-tetrahydrocannabinol (delta-9-tetrahydrocannabinol), Δ¹-tetrahydrocannabinol (using an older numbering scheme), or dronabinol, is the main psychoactive substance found in the Cannabis plant; and additionally so in a variety of other plants. It was isolated by Raphael Mechoulam and Yechiel Gaoni from the Weizmann Institute in Rehovot, Israel in 1964. In pure form it is a glassy solid when cold and becomes viscous and sticky if warmed. THC has a very low solubility in water, but good solubility in most organic solvents such as ethanol or hexane. As in the case of nicotine and caffeine, THC's most likely function in Cannabis is to protect the plant from herbivores or pathogens [1]. THC also possesses high UV-B (280-315 nm) absorption properties, protecting the plant from harmful radiation.

Pharmacology

Its pharmacological actions are the result of its binding to the cannabinoid receptor CB1, located in the brain. The presence of these specialized receptors in the brain implied to researchers that endogenous cannabinoids were manufactured by the body, so the search began for a substance normally manufactured in the brain that binds to these receptors, the so-called natural ligand or agonist, leading to the eventual discovery of anandamide, 2 arachidonyl glyceride (2-AG) and other related compounds. This story resembles the discovery of the endogenous opiates (endorphins, enkephalins, and dynorphin), after the realization that morphine and other opiates bound to specific receptors in the brain. Additionally, it has been shown that cannabinoids, through a presently-unknown mechanism, activate endogenous opioid pathways via the μ1 opioid receptor, precipitating a dopamine release in the nucleus accumbens. This effect can be suppressed by the CB1 cannabinoid receptor antagonist rimonabant (SR141716A) or the opioid receptor antagonist naloxone.[2]

The mechanism of endocannabinoid synaptic transmission is understood by the following events: an excitatory transmission of the neurotransmitter glutamate causes an influx of calcium ions into the post-synaptic neuron. Through a mechanism not yet fully understood, the presence of calcium post-synaptically induces the production of endocannabinoids in the post synaptic neuron. These endocannabinoids (such as anandamide) are released into the synaptic cleft. Once in the synaptic cleft, binding occurs at cannabinoid receptors present in pre-synaptic neurons where they can then modulate neurotransmission presynaptically. This form of neurotransmission is termed retrograde transmission as the signal is carried in the opposite direction of orthodox propagation; it provides an interesting insight into neurotransmission, which previously was thought to be exclusively one way.

THC has analgesic effects that, even at low doses, causes a "high", thus leading to the fact that medical cannabis can be used to treat pain. The mechanism for analgesic effects caused directly by THC or other cannabinoid agonists is not fully elucidated. Other effects include: relaxation; euphoria; altered space-time perception; alteration of visual, auditory, and olfactory senses; disorientation; fatigue; and appetite stimulation related to CB1 receptor activity in the central nervous system. The mechanism for appetite stimulation in subjects is somewhat understood and explained through a gastro-hypothalamic axis. CB1 activity in the hunger centres in the hypothalamus that increase the palatability of food, a hunger hormone--ghrelin increases hunger signals as food enters the stomach. After chyme is passed into the duodenum, signaling hormones such as CCK and leptin are released causing reduction in gastric emptying and satiety signals to the hypothalamus, respectively. Cannabinoid activity is reduced through the satiety signals induced by leptin release. It also has anti-emetic properties, and also may reduce aggression in certain subjects.

THC has an active metabolite, 11-Hydroxy-THC which may also play a role in the analgesic and recreational effects of the herb.

Toxicity

According to the Merck Index, 12th edition, THC has a LD50 value of 1270 mg/kg (male rats) and 730 mg/kg (female rats) administered orally dissolved in sesame oil.[3]

If this were scaled up to an adult human, the LD50 would be between approximately 50 and 86 g for a 68 kg (150 lb) female or male person respectively. This would be equivalent to 1-1.8 kg of cannabis with a 5% THC content (roughly average) taken orally. The LD50 value for rats by inhalation of THC is 42 mg/kg of body weight. It is important to note, however, that toxicity studies in animal models do not necessarily correlate to human toxicity. THC receptor distribution in the rat central nervous system is different from that of humans, meaning that there is the significant possibility that toxicity in humans varies from the published animal LD50 studies. There has never been a documented fatality from marijuana or THC overdose. Absorption is limited by serum lipids which can become saturated with THC, thus the inherent solubility may mitigate toxicity.

Studies of the distribution of the cannabinoid receptors in the brain explain why THC's toxicity is so low (i.e., the LD50 of the compound is so large): parts of the brain that control vital functions such as respiration do not have many receptors, so they are relatively unaffected even by doses larger than could ever be ingested under any normal conditions. There are no known reports of death caused by THC.

See also: Health issues and the effects of cannabis

Research

A number of studies indicate that THC may provide medical benefits for cancer and AIDS patients by increasing appetite and decreasing nausea. It has been shown to assist some glaucoma patients by reducing pressure within the eye, and is used in the form of cannabis by a number of multiple sclerosis patients to relieve the spasms associated with their condition. Recently, cannabis has even been prescribed to adults and teens who are diagnosed with ADD & ADHD due to the drug's relaxing and calming effects.

Studies also indicate a variety of negative effects associated with constant, long-term use, including short-term memory loss. However, other studies have refuted this, claiming the MRIs of long term users show little or no difference to MRIs of the non-using control group. Although using positron emission tomography (PET), at least one study indicates altered memory-related brain function in marijuana users [4]. The long-term effects of THC on humans have been disputed because its status as an illegal drug makes research difficult.

Preliminary research on synthetic THC has been conducted on patients with Tourette syndrome, with results suggesting that it may help in reducing nervous tics and urges by a significant degree. Animal studies suggested that Marinol and nicotine could be used as an effective adjunct to neuroleptic drugs in treating TS. Research on twelve patients showed that Marinol reduced tics with no significant adverse effects. A six-week controlled study on 24 patients showed the patients taking Marinol had a significant reduction in tic severity without serious adverse effects. Seven patients dropped out or had to be excluded from the study, one due to adverse side-effects. More significant reduction in tic severity was reported with longer treatment. No detrimental effects on cognitive functioning and a trend towards improvement in cognitive functioning were reported during and after treatment. Marinol's usefulness as a treatment for TS cannot be determined until/unless longer controlled studies on larger samples are undertaken.[5][6][7][8]

Recent research has shown that many adverse side effects, generally known as the "stoner" stereotype, fail to hold up to the scientific method. Recent studies with synthetic cannabinoids show that activation of CB1 receptors can facilitate neurogeneration, as well as neuroprotection, and can even help prevent natural neural degradation from neurodegenerative diseases such as MS, Parkinson's, and Alzheimer's. This, along with research into the CB2 receptor (throughout the immune system), has given the case for medical marijuana more support.

In in-vitro experiments THC at extremely high concentrations, which could not be reached with commonly consumed doses, caused inhibition of plaque formation, the cause of Alzheimer's disease, better than currently approved drugs.[9]

THC may also be an effective anti-cancer treatment, with studies showing tumor reduction in mice, conducted in 1975.[10]

In early May 2007, British Doctors released a study that linked THC to temporary psychotic episodes (paranoid delusions and hallucinations) in healthy test subjects. Another study conducted at Yale University showed similar results in healthy subjects, but also included a schizophrenic group. The effect on the schizophrenics was so profound that it merited cancellation of subsequent groups in the study due to fear that it would be unethical to continue. [11]

Synthetic THC

Synthetic THC, also known under the substance name dronabinol, is available as a prescription drug (under the trade name Marinol) in several countries including the U.S., The Netherlands, and Germany. In the United States, Marinol is a Schedule III drug, available by prescription, considered to be non-narcotic and to have a low risk of physical or mental dependence. Efforts to get cannabis rescheduled as analogous to Marinol have not succeeded thus far, though a 2002 petition has been accepted by the DEA. As a result of the rescheduling of Marinol from Schedule II to Schedule III, refills are now permitted for this substance. Marinol has been approved by the FDA in the treatment of anorexia in AIDS patients, as well as for refractory nausea and vomiting of patients undergoing chemotherapy.

An analog of dronabinol, nabilone, is available commercially in Canada under the trade name Cesamet, manufactured by Valeant. Cesamet has also received FDA approval for future availability in the United States and is a Schedule II drug.

In April 2005, Canadian authorities approved the marketing of Sativex, a mouth spray for multiple sclerosis to alleviate pain. Sativex contains tetrahydrocannabinol together with cannabidiol. It is marketed in Canada by GW Pharmaceuticals, being the first cannabis-based prescription drug in the world.

See also

References

  1. ^ http://www.madsci.org/posts/archives/jun2000/961475085.Bt.r.html
  2. ^ Carl R Lupica; et al. "Marijuana and cannabinoid regulation of brain reward circuits". Retrieved 2007-07-01. {{cite web}}: Explicit use of et al. in: |author= (help)
  3. ^ Erowid. "Cannabis Chemistry". Retrieved 2006-03-20.
  4. ^ Pharmacology, Biochemistry and Behavior ) 237–250. www.elsevier.com/locate/pharmbiochembeh
  5. ^ PMID
  6. ^ PMID
  7. ^ PMID
  8. ^ PMID
  9. ^ PMID
  10. ^ [1]
  11. ^ [2]


Retrieved from "https://en.wikipedia.org/enwiki/w/index.php?title=Tetrahydrocannabinol&oldid=145273443"